IDH-Based Radiogenomic Characterization of Glioma Using Local Ternary Pattern Descriptor Integrated with Radiographic Features and Random Forest Classifier

Author(s):  
Sonal Gore ◽  
Jayant Jagtap

Mutations in family of Isocitrate Dehydrogenase (IDH) gene occur early in oncogenesis, especially with glioma brain tumor. Molecular diagnostic of glioma using machine learning has grabbed attention to some extent from last couple of years. The development of molecular-level predictive approach carries great potential in radiogenomic field. But more focused efforts need to be put to develop such approaches. This study aims to develop an integrative genomic diagnostic method to assess the significant utility of textures combined with other radiographic and clinical features for IDH classification of glioma into IDH mutant and IDH wild type. Random forest classifier is used for classification of combined set of clinical features and radiographic features extracted from axial T2-weighted Magnetic Resonance Imaging (MRI) images of low- and high-grade glioma. Such radiogenomic analysis is performed on The Cancer Genome Atlas (TCGA) data of 74 patients of IDH mutant and 104 patients of IDH wild type. Texture features are extracted using uniform, rotation invariant Local Ternary Pattern (LTP) method. Other features such as shape, first-order statistics, image contrast-based, clinical data like age, histologic grade are combined with LTP features for IDH discrimination. Proposed random forest-assisted model achieved an accuracy of 85.89% with multivariate analysis of integrated set of feature descriptors using Glioblastoma and Low-Grade Glioma dataset available with The Cancer Imaging Archive (TCIA). Such an integrated feature analysis using LTP textures and other descriptors can effectively predict molecular class of glioma as IDH mutant and wild type.

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Elisabeth Sartoretti ◽  
Thomas Sartoretti ◽  
Michael Wyss ◽  
Carolin Reischauer ◽  
Luuk van Smoorenburg ◽  
...  

AbstractWe sought to evaluate the utility of radiomics for Amide Proton Transfer weighted (APTw) imaging by assessing its value in differentiating brain metastases from high- and low grade glial brain tumors. We retrospectively identified 48 treatment-naïve patients (10 WHO grade 2, 1 WHO grade 3, 10 WHO grade 4 primary glial brain tumors and 27 metastases) with either primary glial brain tumors or metastases who had undergone APTw MR imaging. After image analysis with radiomics feature extraction and post-processing, machine learning algorithms (multilayer perceptron machine learning algorithm; random forest classifier) with stratified tenfold cross validation were trained on features and were used to differentiate the brain neoplasms. The multilayer perceptron achieved an AUC of 0.836 (receiver operating characteristic curve) in differentiating primary glial brain tumors from metastases. The random forest classifier achieved an AUC of 0.868 in differentiating WHO grade 4 from WHO grade 2/3 primary glial brain tumors. For the differentiation of WHO grade 4 tumors from grade 2/3 tumors and metastases an average AUC of 0.797 was achieved. Our results indicate that the use of radiomics for APTw imaging is feasible and the differentiation of primary glial brain tumors from metastases is achievable with a high degree of accuracy.


2019 ◽  
Vol 19 (5) ◽  
pp. 412-416 ◽  
Author(s):  
Emanuela Molinari ◽  
Olimpia E Curran ◽  
Robin Grant

In 2016, the WHO incorporated molecular markers, in addition to histology, into the diagnostic classification of central nervous system (CNS) tumours. This improves diagnostic accuracy and prognostication: oligo-astrocytoma no longer exists as a clinical entity; isocitrate dehydrogenase (IDH) mutant and 1p/19q co-deleted oligodendroglioma is a smaller category with better prognosis; IDH wild-type ‘low-grade’ glioma has a much poorer prognosis; and glioblastoma is divided into IDH mutant (with an better prognosis than pre-2016 glioblastoma) and IDH wild type (with a poorer prognosis). Previous advice based on phenotype alone will change with respect to median survival, best management plan and response to treatment. There are implications for routine neuropathology reporting and future trial design. Cases that are difficult to classify may need more advanced molecular genetic classification through DNA methylation-based classification of CNS tumours (Heidelberg Classifier). We discuss the practical implications.


2018 ◽  
Vol 132 ◽  
pp. 1523-1532 ◽  
Author(s):  
Damodar Reddy Edla ◽  
Kunal Mangalorekar ◽  
Gauri Dhavalikar ◽  
Shubham Dodia

Sign in / Sign up

Export Citation Format

Share Document